| abstract |
The present invention is based, at least in part, on the discovery that the amino terminal domain and the N-linked carbohydrate contained in the amino terminal of C1INH are required for binding of C1INH to LPS. C1INH has the ability to block the binding of LPS to cells, e.g., macrophages. One aspect of the invention provides a method for treating or preventing sepsis in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby treating or preventing sepsis in a subject. In another aspect, the invention provides a method for treating or preventing LPS-mediated inflammation in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby treating or preventing LPS-mediated inflammation in a subject. In yet another aspect, the invention provides a method for suppressing the release of LPS-induced TNF-α in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby suppressing the release of LPS-induced TNF-α in a subject. |